Peripheral artery disease is associated with adverse outcome among hospitalized patients with decompensated heart failure. (14th October 2021)

• Record Type: Journal Article
• Authors: Itelman, E; Maor, E.M; Kuperstein, R.K; Freimark, D.F; Matetzky, S.M; Mazin, I.M
• Is Part Of: European heart journal. Volume 42(2021)Supplement 1
• Publication Date: 2021-10-14
• Subjects: Epidemiology, Prognosis, Outcome; Cardiology -- Periodicals; Heart -- Diseases -- Periodicals; 616.12005
• DOI: 10.1093/eurheartj/ehab724.0811
• Languages: English
• ISSNs: 0195-668X

Abstract

Abstract: : Patients with heart failure (HF) and peripheral artery disease (PAD) share common high co-morbidities and outcomes. Management of HF patients has changed dramatically in the last decade. Our purpose in this analysis was to describe the prognostic significance of PAD in a large contemporary cohort of HF patients. Methods: Analysis included consecutive patients who were hospitalized with decompensated HF between 2008–2020 at our Center. All patients' records were reviewed for the presence of PAD. Patients with cancer or chronic obstructive pulmonary disease were excluded from the analysis. Study outcomes were all-cause mortality and HF hospitalizations. Cox regression and propensity score matching models were applied. Results: Final study population included 8, 216 patients of whom 548 (7%) had PAD. Patients with PAD had higher rates of co-morbidities. Median follow-up was 3 (IQR 1–7) years. PAD was associated with a significant 35% increased risk of re-admission and mortality in univariate analysis (p<.001 for both). Propensity score matching analysis has demonstrated that PAD patients had similar mortality rates, but higher re-hospitalization rates during follow up. Finally, sensitivity analysis of the matching model (n=474), after excluding patients with RV dysfunction or severe pulmonary hypertension, successfully showed that HF patients with PAD were 50% more likely to be re-admitted and 30% more likely to die during follow-up (p=0.02 and 0.006 respectively; Figure 1) Funding Acknowledgement: Type of funding sources: None.